The ACME Laboratories Limited (As per Prospectus)

Nature of Business	The Company is engaged in manufacturing, marketing and distribution of generic pharmaceuticals formulation products.	
Major Products	The main products and services of The ACME Laboratories Limited are: 1. Human drugs dosages: Tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatin, sachet products, IV infusion.	
	 Veterinary drugs dosages: Bolus, liquid, injection, water soluble powder, premix. Herbal drugs dosages: Liquid, capsule, tablet, cream & 	
	ointment.	
Security Trading Code	ACMELAB	
Subscription Open	April 11, 2016	
Subscription Close (Cut-off Date)	April 21, 2016	
Authorized Capital	Tk. 5,000,000,000	
Pre-IPO paid-up Capital	Tk. 1,616,017,000	
IPO size in shares	50,000,000 including 25,000,000 shares for Ells and 5,000,000 shares for Mutual Funds	
IPO size in Tk. at face value	Tk. 500,000,000	
IPO size in Tk. at offer price	Tk. 4,096,000,000	
Post IPO Paid-up Capital	Tk. 2,116,017,000	
Face Value per share	Tk. 10.00	
Indicative Price per share	Tk. 71.00	
Cut-Off Price per share	Tk. 85.20	
Offer Price per share for General Public	Tk. 77.00	
Market Lot (Shares)	100	
Foreign Currency required for NRB and Foreign Applicants (per lot)	USD 98.72 or GPB 70.03 or EUR 89.40	
Use of IPO Proceeds	Steroid & Hormone	135.80 crore (31.49%)
	Oncology	114.10 crore (26.46%)
	Ayurvedic, Modern Herbal and Nutraceuticals	174.55 crore (40.47%)
	IPO Expenses	6.83 crore (1.58%)
	Total Th. 70.27 (including revaluation curplus) as	431.28 crore (100.00%)
NAV per share	Tk. 70.37 (including revaluation surplus) and Tk. 37.45 (excluding revaluation surplus) as at 30 June, 2015	
EPS	Tk. 5.70 for the year ended on 30 June, 2015	
Issue Manager	ICB Capital Management Limited	
Registrar to the Issue	Prime Finance Capital Management Limited	
Auditors	Pinaki & Company	
Website	www.acmeglobal.com	